David J Lederer

David J Lederer

Regeneron Pharmaceuticals Inc - Warsaw / United States
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 4394000
-
person_outline David J Lederer's MOST POPULAR ARTICLES
1-) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosisL Richeldi, RM Du Bois, G Raghu, A Azuma, KK Brown, U Costabel, ...New England Journal of Medicine 370 (22), 2071-2082, 201435812014
2-) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosisTE King Jr, WZ Bradford, S Castro-Bernardini, EA Fagan, I Glaspole, ...New England Journal of Medicine 370 (22), 2083-2092, 201431902014
3-) Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guidelineG Raghu, M Remy-Jardin, JL Myers, L Richeldi, CJ Ryerson, DJ Lederer, ...American journal of respiratory and critical care medicine 198 (5), e44-e68, 201821932018
4-) Idiopathic pulmonary fibrosisDJ Lederer, FJ MartinezNew England Journal of Medicine 378 (19), 1811-1823, 201818122018
5-) A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung …D Weill, C Benden, PA Corris, JH Dark, RD Davis, S Keshavjee, ...The Journal of Heart and Lung Transplantation 34 (1), 1-15, 201515282015